We are excited to announce that the repository will soon undergo an upgrade, featuring a new look and feel along with several enhanced features to improve your experience. Please be on the lookout for further updates and announcements regarding the launch date. We appreciate your support and look forward to unveiling the improved platform soon.
dc.contributor.author | Said, Halima Mohammed![]() |
|
dc.contributor.author | Kock, Marleen M.![]() |
|
dc.contributor.author | Ismail, Nazir Ahmed![]() |
|
dc.contributor.author | Baba, Kamaldeen A.![]() |
|
dc.contributor.author | Omar, Shaheed Vally![]() |
|
dc.contributor.author | Osman, Ayman Gassim Elamin![]() |
|
dc.contributor.author | Hoosen, Anwar Ahmed![]() |
|
dc.contributor.author | Ehlers, Marthie Magdaleen![]() |
|
dc.date.accessioned | 2012-03-19T06:55:21Z | |
dc.date.available | 2012-03-19T06:55:21Z | |
dc.date.issued | 2012-01 | |
dc.description.abstract | BACKGROUND: The GenoType® MTBDRsl assay (Hains, Lifesciences, Germany) is a new rapid assay for detection of resistance to second-line anti-tuberculosis drugs. METHOD: The MTBDRsl assay was evaluated on 342 MDR-TB isolates for ofloxacin (OFX), kanamycin (KAN), capreomycin (CAP) and ethambutol (EMB) resistance and results were compared to the agar proportion method. Discrepant results were tested by DNA sequencing. RESULT: The sensitivity and specificity of MTBDRsl assay was 70.3% and 97.7% for OFX, 25.0% and 98.7% for KAN, 21.2% and 98.7% for CAP and 56.3% and 56.0% for EMB, respectively. DNA sequencing identified mutation that were not detected by MTBDRsl assay including: 8/11 phenotypically OFX-resistant isolates had mutation in gyrA (2/8 had additional mutation in the gyrB gene), 1/11 had mutation only in the gyrB gene; 6/21 phenotypically KAN-resistant isolate had mutation in rrs gene; 7/26 and 20/26 phenotypically CAP-resistant isolates had mutation in the rrs and tlyA genes, respectively. CONCLUSION: The MTBDRsl assay showed a lower sensitivity as compared to previous studies. The assay performed favourably for OFX; however the assay was less sensitive for detection of KAN/CAP resistance and demonstrated low sensitivity and specificity for EMB resistance. It is recommended that the MTBDRsl assay should include additional genes to achieve a better sensitivity for all the drugs tested. | en_US |
dc.description.sponsorship | A grant from the NHLS and Hains, Lifesciences. | en_US |
dc.description.uri | http://www.theunion.org/about-the-journal/about-the-journal.html | en_US |
dc.identifier.citation | Said, HM, Kock, MM, Ismail, NA, Baba, K, Omar, SV, Osman, AG, Hoosen, AA & Ehlers, MM 2012, 'Evaluation of the GenoType (R) MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs', International Journal of Tuberculosis and Lung Disease, vol. 16, no. 1, pp. 104-109. | en_US |
dc.identifier.issn | 1027-3719 (print) | |
dc.identifier.issn | 1815-7920 (online) | |
dc.identifier.uri | http://hdl.handle.net/2263/18471 | |
dc.language.iso | en | en_US |
dc.publisher | International Union Against Tuberculosis and Lung Disease | en_US |
dc.rights | International Union Against Tuberculosis and Lung Disease. This article is embargoed by the publisher until July 2012. | en_US |
dc.subject | MDR-TB | en_US |
dc.subject | XDR-TB | en_US |
dc.subject | Genotype® MTBDRsl | en_US |
dc.subject | Drug resistance | en_US |
dc.subject.lcsh | Tuberculosis -- Treatment | en |
dc.subject.lcsh | Multidrug resistance -- Research | en |
dc.title | Evaluation of the GenoType (R) MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs | en_US |
dc.type | Postprint Article | en_US |